The antihyperglycaemic effect has been proven by the recent SURPASS (efficacy and safety of a novel dual GIP and GLP-1 RA tirzepatide in patients with Type 2 diabetes) trials, where subcutaneous tirzepatide 5, 10 and 15 mg once weekly were compared to placebo, semaglutide, dulaglutide and basal insulin [20–25]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.